Toronto, Ontario – November 2, 2023 – Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) (the “Company” or “Predictmedix”), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce that it has been invited to the D-30 event to showcase its impairment screening technology, which is an international gathering of 30 nations focused on combating drug addiction on a global scale.
The D-30 event represents a significant milestone in the fight against drug addiction and disabilities caused by drug addiction, symbolizing the collaboration of 30 nations recognized by the United Nations for their dedicated efforts in tackling drug addiction on a global scale. The primary goal of the program is to draw attention to the pressing issue of drug abuse and foster international unity in addressing addiction.
The utility of Predictmedix technology is not only in identification of impairment (caused by alcohol or drugs such as cannabis) but also in managing the health of patients that are coming into addiction centers by monitoring their vital parameters in real-time and looking at trends for better management/diagnosis as they recover from the underlying drug addiction. Therefore the utility of the technology is both for de-addiction treatment and managing disability caused by it which is useful for patients, students, workers and the overall industry for creating a safer drug free world.
Details of the D-30 event are as follows:
- Program: D-30, and Cultural Event
- Date: Saturday, November 4, 2023
- Time: 10:00 AM to 5:00 PM
- Venue: Hotel The Lalit, New Delhi, India
Predictmedix AI will be actively involved in the event, showcasing its cutting-edge impairment screening technology, which has the potential to play a significant role in addressing drug addiction issues.
Predictmedix has achieved over 90 per cent accuracy in identifying impaired individuals using a combination of multispectral imaging and speech analysis, as demonstrated in the company’s latest study. As the technology is powered by artificial intelligence, its accuracy rate is only expected to increase with time, thanks to the deep learning and machine learning algorithms that allow the system to learn and adapt from new data.
Dr. Rahul Kushwah, COO of Predictmedix AI, expressed his enthusiasm for this opportunity: “We are excited to be participating in the D-30 event and we thank the organizers for inviting and showcasing our impairment screening technology in this global forum focusing on combating drug addiction globally. Predictmedix AI is committed to leveraging innovation to combat drug addiction and related issues, and this event aligns perfectly with our mission.”
Furthermore, Predictmedix AI is pleased to introduce Colonel G. Srikumar (Retd), an accomplished veteran of the Indian Army, as the new director of Predictmedix India Pvt Ltd. Colonel Srikumar has joined the company to accelerate business development in key sectors across India. His wealth of experience and dedication will contribute significantly to Predictmedix AI’s growth and impact in the region. The utility of Predictmedix AI technology ranges from healthcare, sporting industry, workplace safety to defense segment and Colonel Srikumar will be assisting the company to accelerate business development in these segments in India along with key international markets in Africa and the Middle East.
The Company will issue 62,250 common shares as consideration for the services provided by a marketing consultant to the Company. The shares will be subject to a hold period of 4 months from the date of issuance.
About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn. To receive company news, please sign up for alerts on https://predictmedix.com/contact-us.
Public Relations Contact
For further media information or to set up an interview, please contact:
Communications International (905) 660 9155
Dr. Rahul Kushwah (647) 889 6916
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: “The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.